Valeant Pharmaceuticals International, Inc. announced it put in notice to pay down an additional $200 million of its senior secured term loans, using cash on hand. When the debt is repaid next week, Valeant will have reduced its debt, in aggregate, by more than $6.7 billion since the end of the first quarter of 2016, and the Company's total long-term debt will be approximately $25.5 billion.